Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)

TipRanksSep 5 08:20 ET · Ratings

IO Biotech IOBT Analyst; Vaxvyte PCVX Phase 1/2 Data

BioPharmCatalystSep 3 15:36 ET

Express News | Piper Sandler Maintains Overweight on IO Biotech, Maintains $10 Price Target

BenzingaSep 3 09:57 ET

Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsSep 3 08:33 ET · Ratings

Express News | IO Biotech Shares Are Trading Lower After the Company Announced the IDMC Observed No New Safety Signals in the Phase 3 Trial of IO102-IO103. Also, Morgan Stanley Maintained an Overweight Rating on the Stock but Lowered Its Price Target From $7 to $4

BenzingaSep 3 08:19 ET

Optimistic Outlook on IO Biotech's PFS Improvements Despite ORR Setback

TipRanksSep 3 06:15 ET